1. Judith Hsia jhsia@mfa.gwu.edu 202-741-2321

2. Hormone Therapy Trial: Coronary Heart Disease & Fractures. Adverse effect for Breast Cancer? Calcium/Vitamin D Trial: Fractures & Colorectal Cancer Dietary Modification Trial: Breast & Colorectal Cancers & Coronary Heart Disease 93,676 Observational Study 48,835 36,282 3 Controlled Trials 1 Observational Study 27,347 161,808 women total Women’s Health Initiative

3. CV risk with PreHTN NormalPrehypertensionHypertension N (Ann %) HR N (Ann %)HR (95% CI) N (Ann %) HR (95% CI) CVdeath 83 (0.07) 1 219 (0.12) 1.58 (1.12, 2.21) 510 (0.32) 3.02 (2.18, 4.18) MI 177 (0.14) 1 442 (0.24) 1.76 (1.40, 2.22) 770 (0.48) 2.86 (2.28, 3.59) Stroke 137 (0.11) 1 407 (0.22) 1.93 (1.49, 2.50) 778 (0.49) 3.62 (2.82, 4.66) CHF 137 (0.11) 1 351 (0.19) 1.36 (1.05, 1.77) 848 (0.53) 2.78 (2.17, 3.57) Any CV event 442 (0.35) 1 1196 (0.66) 1.66 (1.44, 1.92) 2253 (1.41) 2.89 (2.52, 3.32) Stratified by age and trial participation; adj for age, BMI, DM, high chol and smoking

4. Other studies “Pilot study to identify novel biomarkers of myocardial necrosis” “Pilot study to identify novel biomarkers of myocardial necrosis” American Red Cross; David Hammond, PI American Red Cross; David Hammond, PI Selenium and Vitamin E Chemoprevention Trial (SELECT) Selenium and Vitamin E Chemoprevention Trial (SELECT) NCI via subcontract with SWOG NCI via subcontract with SWOG Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer National Cancer Institute of Cancer National Cancer Institute of Cancer